Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Adriana M. Ivama-Brummell"'
Autor:
Adriana M. Ivama-Brummell, Fernanda L. Marciniuk, Anita K. Wagner, Claudia G.S. Osorio-de-Castro, Sabine Vogler, Elias Mossialos, Carla L. Tavares-de-Andrade, Huseyin Naci
Publikováno v:
The Lancet Regional Health. Americas, Vol 22, Iss , Pp 100506- (2023)
Summary: Background: Most cancer drugs enter the US market first. US Food and Drug Administration (FDA) approvals of new cancer drugs may influence regulatory decisions in other settings. The study examined whether characteristics of available eviden
Externí odkaz:
https://doaj.org/article/c91ea72b5e9b4153a9c6acbbc454a7e2
Publikováno v:
Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde, Vol 13, Iss 4 (2022)
The special series “Pharmaceutical Pricing and Reimbursement Policies” published throughout 2022, was organised by invitation of the Brazilian Journal of Hospital Pharmacy and Health Services, to characterise medicines pricing and reimbursement i
Externí odkaz:
https://doaj.org/article/f8a39d8f1125448ebe22e222ae348993
Publikováno v:
Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde, Vol 13, Iss 2 (2022)
The United Kingdom has universal healthcare systems, the National Health System (NHS), in its four nations, with healthcare services provided free of charge at the point of delivery. Approximately 10.5% of the UK population has voluntary supplementar
Externí odkaz:
https://doaj.org/article/6b973df009a842b082bcc4ebd1a76b76
Autor:
Adriana M. IVAMA-BRUMMELL, Daniella PINGRET-KIPMAN, Claudia S. OSORIO-DE-CASTRO, Jaime ESPÍN, Vania C. CANUTO-SANTOS, Romilson A. VOLOTÃO, Augusto A. GUERRA-JUNIOR, Gabriela B. MOSEGUI
Publikováno v:
Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde, Vol 13, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/87ce02a5097a460aa77b838b0b1c99f6
Publikováno v:
Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde, Vol 13, Iss 1 (2022)
Brazil is an upper-middle-income country with a high human development index (HDI) of 0.765 (2019). The Unique Health System (SUS) is a universal, decentralised system, free at point-of-care, although 27% of Brazilians have voluntary supplementary he
Externí odkaz:
https://doaj.org/article/84b0b8aeffd44da7bd30fdf30ebc6b71
Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysis
Autor:
Adriana M. Ivama-Brummell, Fernanda L. Marciniuk, Anita K. Wagner, Claudia G.S. Osorio-de-Castro, Sabine Vogler, Elias Mossialos, Carla L. Tavares-de-Andrade, Huseyin Naci
Background: Most cancer drugs enter the US market first. US Food and Drug Administration (FDA) approvals of new cancer drugs may influence regulatory decisions in other settings. The study examined whether characteristics of available evidence at FDA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99f0902c5195004030397fce480093aa
http://eprints.lse.ac.uk/118777/
http://eprints.lse.ac.uk/118777/